Takeda Subsidiary Seeks $130M For Drug Firm's Spinoff Fraud

Law360 (September 22, 2020, 9:57 PM EDT) -- A Takeda subsidiary told the Delaware Chancery Court on Tuesday that it should get $130 million in damages from immunotherapy drug developer Harpoon Therapeutics, after a vice chancellor found that Harpoon fraudulently induced it into buying into a cancer therapy research and investment opportunity.

After an all-day virtual trial to consider damages in the case, Vice Chancellor Sam Glasscock III suggested the parties consider heading to mediation since they are so far apart regarding the amount of damages that should be awarded. A Harpoon expert argues that damages should be as low as $400,000, according to comments during Tuesday's trial....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!